Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1974 1
1975 1
1976 2
1977 1
1980 1
1981 2
1983 3
1984 2
1985 6
1986 2
1987 6
1988 4
1989 3
1990 2
1991 7
1992 3
1993 5
1994 3
1995 5
1996 10
1997 9
1998 10
1999 12
2000 17
2001 13
2002 11
2003 10
2004 17
2005 15
2006 15
2007 16
2008 15
2009 12
2010 27
2011 23
2012 32
2013 33
2014 31
2015 26
2016 30
2017 32
2018 38
2019 47
2020 66
2021 59
2022 56
2023 55
2024 21

Text availability

Article attribute

Article type

Publication date

Search Results

721 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Hypotrichosis 10"
Page 1
Superficial fungal infections.
Kovitwanichkanont T, Chong AH. Kovitwanichkanont T, et al. Aust J Gen Pract. 2019 Oct;48(10):706-711. doi: 10.31128/AJGP-05-19-4930. Aust J Gen Pract. 2019. PMID: 31569324 Free article. Review.
Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial.
King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, Mesinkovska NA, Zwillich SH, Napatalung L, Wajsbrot D, Fayyad R, Freyman A, Mitra D, Purohit V, Sinclair R, Wolk R. King B, et al. Lancet. 2023 May 6;401(10387):1518-1529. doi: 10.1016/S0140-6736(23)00222-2. Epub 2023 Apr 14. Lancet. 2023. PMID: 37062298 Clinical Trial.
FINDINGS: Between Dec 3, 2018, and June 24, 2021, 1097 patients were screened and 718 were randomly assigned to receive ritlecitinib 200 mg + 50 mg (n=132), 200 mg + 30 mg (n=130), 50 mg (n=130), 30 mg (n=132), 10 mg (n=63), placebo to 50 mg (n=66), or placebo to 200 mg + …
FINDINGS: Between Dec 3, 2018, and June 24, 2021, 1097 patients were screened and 718 were randomly assigned to receive ritlecitinib 200 mg …
Mesotherapy With Dutasteride for Androgenetic Alopecia: A Retrospective Study in Real Clinical Practice.
Saceda-Corralo D, Moustafa F, Moreno-Arrones Ó, Jaén-Olasolo P, Vañó-Galván S, Camacho F. Saceda-Corralo D, et al. J Drugs Dermatol. 2022 Jul 1;21(7):742-747. doi: 10.36849/JDD.6610. J Drugs Dermatol. 2022. PMID: 35816059
This therapy may be an effective option for select patients wishing to avoid oral treatment. J Drugs Dermatol. 2022;21(7):742-747. doi:10.36849/JDD.6610....
This therapy may be an effective option for select patients wishing to avoid oral treatment. J Drugs Dermatol. 2022;21(7):742-747. doi:10 …
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E; American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE); Androgen Excess and PCOS Society (AES). Goodman NF, et al. Endocr Pract. 2015 Nov;21(11):1291-300. doi: 10.4158/EP15748.DSC. Endocr Pract. 2015. PMID: 26509855
New ultrasound machines allow diagnosis of PCOM in patients having at least 25 small follicles (2 to 9 mm) in the whole ovary. Ovarian size at 10 mL remains the threshold between normal and increased ovary size. ...
New ultrasound machines allow diagnosis of PCOM in patients having at least 25 small follicles (2 to 9 mm) in the whole ovary. Ovarian size …
Interventions for female pattern hair loss.
van Zuuren EJ, Fedorowicz Z, Schoones J. van Zuuren EJ, et al. Cochrane Database Syst Rev. 2016 May 26;2016(5):CD007628. doi: 10.1002/14651858.CD007628.pub4. Cochrane Database Syst Rev. 2016. PMID: 27225981 Free PMC article. Review.
There was an important increase of 13.18 in total hair count per cm2 in the minoxidil group compared to the placebo group (95% CI 10.92 to 15.44; low quality evidence) in eight studies (1242 participants). ...
There was an important increase of 13.18 in total hair count per cm2 in the minoxidil group compared to the placebo group (95% CI 10. …
Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation.
Ghonemy S, Alarawi A, Bessar H. Ghonemy S, et al. J Dermatolog Treat. 2021 Mar;32(2):236-241. doi: 10.1080/09546634.2019.1654070. Epub 2019 Oct 21. J Dermatolog Treat. 2021. PMID: 31403367 Clinical Trial.
Although other concentrations (2% to 12.5%) are available nowadays, we believe our study is the first to compare 10% versus 5% topical minoxidil in treatment of AGA. OBJECTIVE: To compare the efficacy and safety of 5% topical minoxidil with 10% topical minoxidil and …
Although other concentrations (2% to 12.5%) are available nowadays, we believe our study is the first to compare 10% versus 5% topica …
Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial.
Hordinsky M, Hebert AA, Gooderham M, Kwon O, Murashkin N, Fang H, Harada K, Law E, Wajsbrot D, Takiya L, Zwillich SH, Wolk R, Tran H. Hordinsky M, et al. Pediatr Dermatol. 2023 Nov-Dec;40(6):1003-1009. doi: 10.1111/pde.15378. Epub 2023 Jul 17. Pediatr Dermatol. 2023. PMID: 37455588 Clinical Trial.
METHODS: In ALLEGRO-2b/3, patients aged 12 years with AA and 50% scalp hair loss received once-daily ritlecitinib 50 or 30 mg (4-week 200-mg loading dose) or 10 mg or placebo for 24 weeks. In a subsequent 24-week extension period, ritlecitinib groups continued their doses, …
METHODS: In ALLEGRO-2b/3, patients aged 12 years with AA and 50% scalp hair loss received once-daily ritlecitinib 50 or 30 mg (4-week 200-mg …
Janus Kinase Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis.
Liu M, Gao Y, Yuan Y, Yang K, Shen C, Wang J, Tian J. Liu M, et al. JAMA Netw Open. 2023 Jun 1;6(6):e2320351. doi: 10.1001/jamanetworkopen.2023.20351. JAMA Netw Open. 2023. PMID: 37368402 Free PMC article.
RESULTS: Seven RCTs with 1710 patients (1083 females [63.3%]; mean [SD] age range, 36.3 [10.4] to 69.7 [16.2] years) were eligible and included in the study. ...The subgroup analysis showed that oral JAK inhibitors were more efficient than placebo (change from baseline SAL …
RESULTS: Seven RCTs with 1710 patients (1083 females [63.3%]; mean [SD] age range, 36.3 [10.4] to 69.7 [16.2] years) were eligible an …
The effects of magnesium supplementation on abnormal uterine bleeding, alopecia, quality of life, and acne in women with polycystic ovary syndrome: a randomized clinical trial.
Jaripur M, Ghasemi-Tehrani H, Askari G, Gholizadeh-Moghaddam M, Clark CCT, Rouhani MH. Jaripur M, et al. Reprod Biol Endocrinol. 2022 Aug 2;20(1):110. doi: 10.1186/s12958-022-00982-7. Reprod Biol Endocrinol. 2022. PMID: 35918728 Free PMC article. Clinical Trial.
METHODS: In this parallel randomized clinical trial, we randomly assigned 64 women with PCOS to the magnesium group (n = 32) or placebo group (n = 32) for 10 weeks. AUB, alopecia, quality of life, and acne were assessed by the International Federation of Gynecology and Obs …
METHODS: In this parallel randomized clinical trial, we randomly assigned 64 women with PCOS to the magnesium group (n = 32) or placebo grou …
721 results